Zerr I, Schulz-Schaeffer W J, Giese A, Bodemer M, Schröter A, Henkel K, Tschampa H J, Windl O, Pfahlberg A, Steinhoff B J, Gefeller O, Kretzschmar H A, Poser S
Department of Neurology, Georg-August-University, Göttingen, Germany.
Ann Neurol. 2000 Sep;48(3):323-9.
According to the recently established molecular basis for phenotypic heterogeneity of sporadic Creutzfeldt-Jakob disease (CJD), six different phenotypes are characterized by the size of the protease-resistant fragment of the pathological prion protein (types 1 and 2) and homozygosity or heterozygosity for methionine or valine at codon 129 of the prion protein gene (designated by MM1, MM2, MV1, MV2, W1, and W2). In the present investigation, we analyzed the value of commonly used clinical tests (electroencephalogram [EEG], detection of 14-3-3 protein in cerebrospinal fluid [CSF], and hyperintensity of the basal ganglia in magnetic resonance imaging) for the clinical diagnosis in each CJD phenotype. The detection of periodic sharp and slow wave complexes in the EEG is reliable in the clinical diagnosis of MM1 and MV1 patients only. The CSF analysis for 14-3-3 protein showed high sensitivity in all analyzed subgroups with the exception of MV2 patients. Valine-homozygous patients had a negative EEG, but most had detectable levels of neuronal proteins in the CSF. The sensitivity of the magnetic resonance imaging was 70%, irrespective of the subgroup, but was particularly reliable in the clinical diagnosis of MV2 patients. The widening spectrum of diagnostic techniques in CJD is not only useful in the increased accuracy of the clinical diagnosis but should also lead to the identification of more atypical cases of sporadic CJD.
根据最近确立的散发性克雅氏病(CJD)表型异质性的分子基础,六种不同的表型由病理性朊蛋白蛋白酶抗性片段的大小(1型和2型)以及朊蛋白基因第129密码子处甲硫氨酸或缬氨酸的纯合性或杂合性来表征(分别命名为MM1、MM2、MV1、MV2、W1和W2)。在本研究中,我们分析了常用临床检测方法(脑电图[EEG]、脑脊液[CSF]中14-3-3蛋白的检测以及磁共振成像中基底神经节的高信号)对各CJD表型临床诊断的价值。脑电图中周期性尖慢复合波的检测仅在MM1和MV1患者的临床诊断中可靠。CSF中14-3-3蛋白的分析在所有分析的亚组中显示出高敏感性,但MV2患者除外。缬氨酸纯合子患者脑电图为阴性,但大多数患者CSF中可检测到神经元蛋白水平。磁共振成像的敏感性为70%,与亚组无关,但在MV2患者的临床诊断中特别可靠。CJD诊断技术范围的拓宽不仅有助于提高临床诊断的准确性,还应能识别出更多散发性CJD的非典型病例。